
|Articles|December 13, 2004
Heart drugs under study focus on impact on metabolism
Some help for battling the obesity epidemic may be arriving, according to continuing encouraging results for rimonabant (Acomplia, Sanofi-Aventis), not just in helping weight loss but also in improving metabolic risk factors. Other research at this year's American Heart Association 2004 Scientific Sessions, held recently in New Orleans, focused, as well, on metabolic effects of pharmacological agents.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
2
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
3
What TrumpRx Means for Independent Pharmacies and Their Patients
4
Limited Clinical Data Impact Cannabis Integration Into Standard Care | ASHP Midyear 2025
5




























































































































